ALLOGENE THERAPEUTICS INC
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
ALLOGENE THERAPEUTICS INC
Founded:
2017-01-01
Status:
Active
Email Addresses:
[email protected]
Total Funding:
120 M USD
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-02-10 | Notch Therapeutics | Allogene Therapeutics Inc investment in Series A - Notch Therapeutics | 85 M USD |
| 2019-11-06 | Notch Therapeutics | Allogene Therapeutics Inc investment in Corporate Round - Notch Therapeutics | 1000 K USD |
More informations about "Allogene Therapeutics Inc"
About Us - Allogene
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell …See details»
Allogene Therapeutics - Crunchbase Investor Profile & Investments
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy. CIO, Information Officer View contacts for Allogene …See details»
Allogene Therapeutics - The Org
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR Tâ„¢) therapies for cancer.See details»
Allogene Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Allogene Therapeutics, Inc. of South San Francisco, CA. Get the latest business insights from Dun & …See details»
Allogene Therapeutics, Inc. - AnnualReports.com
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T …See details»
Allogene Therapeutics, Inc. (ALLO) Company Profile & Overview
Oct 11, 2018 Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of …See details»
Allogene Therapeutics, Inc. (ALLO): history, ownership ... - dcf-fm
Nov 16, 2024 Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on pioneering the development of genetically engineered allogeneic T cell product candidates …See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.See details»
Allogene Therapeutics - Company Profile - Tracxn
3 days ago What does Allogene Therapeutics do? Developer of chimeric antigen receptor cell therapy to treat cancer. The lead candidate of the company ALLO-501A targets CD-19 in …See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance Canada
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.See details»
Company Allogene Therapeutics, Inc. - MarketScreener.com
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the …See details»
Allogene Therapeutics Inc, ALLO:NSQ profile - FT.com
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the …See details»
Allogene Therapeutics - Funding, Financials, Valuation & Investors
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.See details»
Allogene Therapeutics - Contacts, Employees, Board Members
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.See details»
Allogene Therapeutics, Inc. (ALLO) - Yahoo Finance
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.See details»
Allogene Therapeutics Inc, ALLO:NSQ summary - FT.com
Nov 27, 2024 Latest Allogene Therapeutics Inc (ALLO:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.See details»
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
Nov 25, 2024 Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the …See details»
Allogene Therapeutics Announces Publication of Industry …
Mar 1, 2023 Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen …See details»
Allogene Therapeutics Receives FDA Regenerative Medicine …
Oct 29, 2024 About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of …See details»
News Center - Allogene
NEWS CENTER LEARN ABOUT AlloCAR Tâ„¢ PRODUCTS LATEST PRESS RELEASES Apr 26, 2024 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative …See details»